GSK Accelerates Velzatinib Phase III Trial Following Promising First-Line GIST Results
Key Insights
GSK will present first-time data from velzatinib (search) in first-line gastrointestinal stromal tumors (search) (GIST (search)) at ASCO 2026, showing a 61% response rate in 18 patients from the phase Ib StrateGIST 1 study.
The promising early results have accelerated initiation of the StrateGIST Frontline phase III trial, which will compare velzatinib (search) against imatinib (Gleevec) with overall survival as the primary endpoint.
Velzatinib (search) demonstrates broad activity across clinically relevant KIT (search) mutations and substantial circulating tumor DNA clearance, addressing a key unmet need in GIST (search) treatment.
GSK is advancing its oncology pipeline with promising early data for velzatinib (search), an investigational KIT (search) inhibitor, in first-line gastrointestinal stromal tumors (search) (GIST (search)). The pharmaceutical giant will present first-time results from the phase Ib StrateGIST 1 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showing encouraging activity that has accelerated the start of a pivotal phase III trial.
Strong Response Rates Drive Phase III Acceleration
The StrateGIST 1 study demonstrated a 61% response rate among 18 first-line GIST (search) patients, though all responses remain unconfirmed as of the December 15, 2025 data cutoff. These results have prompted GSK to accelerate initiation of the StrateGIST Frontline phase III clinical trial, which is set to begin in June 2026.
The phase III study will compare velzatinib (search) against imatinib (Gleevec) with overall survival as the primary endpoint. This represents a significant milestone for GSK, which had previously planned to start the trial in the second half of 2026, indicating the company is ahead of schedule based on the encouraging early data.
Addressing Critical Unmet Need in GIST
Velzatinib (search)'s development addresses a significant gap in GIST (search) treatment. According to GSK, approximately 80% of GIST cases are driven by mutations in the KIT (search) gene, with about 90% of patients treated in first-line developing new KIT mutations that typically lead to relapse with limited therapeutic options. Currently, there are no approved tyrosine kinase inhibitors that inhibit the full spectrum of clinically relevant primary and secondary mutations in KIT.
Data to be presented at ASCO will demonstrate velzatinib (search)'s broad activity across clinically relevant KIT (search) mutations in all treatment lines, including first-line and second-line advanced GIST (search). The drug shows encouraging anti-tumor activity and tolerability, supporting the potential for a differentiated clinical profile.
Additional analyses will highlight velzatinib (search)'s substantial circulating tumor DNA (ctDNA) clearance of clinically meaningful KIT (search) mutations and inhibition of GIST (search) tumor cells, providing further evidence of its mechanism of action.
Competitive Landscape and Strategic Positioning
GSK acquired velzatinib (search) through its $1 billion acquisition of IDRx (search) in January 2025, positioning the company to compete in the evolving KIT (search) inhibitor market. The company is ahead of competitor Cogent Biosciences, which plans to begin a phase II first-line study with its KIT inhibitor bezuclastinib in the first half of 2026.
Cogent has already filed bezuclastinib in combination with sunitinib with the FDA based on results from the Peak study in post-imatinib patients, where the combination reduced the risk of progression or death by 50% versus sunitinib alone. However, GSK's move into first-line treatment could provide a competitive advantage if velzatinib (search) demonstrates superiority over the current standard of care.
Regulatory Status and Development Timeline
The US Food and Drug Administration has granted velzatinib (search) Fast Track designation for treatment of patients with GIST (search) after disease progression on or intolerance to imatinib, along with Orphan Drug designations for GIST treatment. These regulatory designations support accelerated development and review processes.
GSK is also conducting the StrateGIST 3 trial, a randomized phase III study comparing velzatinib (search) versus sunitinib in patients with advanced GIST (search) after imatinib therapy, providing multiple pathways for potential approval across different treatment lines.
Market Context and Clinical Impact
GIST (search) represents the most common subtype of soft tissue sarcoma (search), with approximately 80,000 to 120,000 patients diagnosed worldwide annually. The current treatment landscape relies heavily on imatinib as first-line therapy, which received accelerated approval in 2002 based on a 53% overall response rate in a phase II trial that included previously treated patients.
The development of velzatinib (search) and competing KIT (search) inhibitors reflects the ongoing need for improved therapies that can address the full spectrum of KIT mutations and provide durable responses for GIST (search) patients. Success in first-line treatment could significantly impact patient outcomes and establish new standards of care in this rare cancer indication.